Loading...
•
Dec 31, 2025
Ironwood Pharmaceuticals Q4 2025 Earnings Report
Ironwood Pharmaceuticals reported lower fourth quarter 2025 revenue and a GAAP net loss driven by reduced LINZESS collaboration revenue and margin compression.
Key Takeaways
In Q4 2025, Ironwood generated total revenue of 47709000, reported a GAAP net loss of 2276000, and recorded adjusted EBITDA of 10913000, reflecting lower LINZESS U.S. net sales and a decline in commercial margin.
Total revenue declined to 47709000 from 90545000 year-over-year.
GAAP net loss was 2276000 compared to GAAP net income of 2256000 in Q4 2024.
LINZESS U.S. net sales were 163173000, down 27% year-over-year.
LINZESS commercial margin decreased to 54% from 64% year-over-year.
Revenue by Segment
Forward Guidance
For full year 2026, Ironwood expects U.S. LINZESS net sales of 1125000000 to 1175000000, total revenue of 450000000 to 475000000, and adjusted EBITDA of greater than 300000000.
Positive Outlook
- Expected U.S. LINZESS net sales of 1125000000 to 1175000000 in 2026.
- Projected total revenue of 450000000 to 475000000 in 2026.
- Adjusted EBITDA guidance of greater than 300000000.
- Disciplined expense management supporting profitability.
- Improved net price and low-single digit demand growth expected in 2026.
Challenges Ahead
- Q4 2025 revenue declined significantly year-over-year.
- Commercial margin compressed to 54% from 64%.
- GAAP net loss in Q4 2025.
- Pricing headwinds from Medicare Part D redesign.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...